Five things for pharma marketers to know: Wednesday, August 3, 2016

1. Merck and Allergan have expressed interest in buying Biogen, sources told The Wall Street Journal. Biogen, which markets multiple-sclerosis drugs like Tecfidera, has a market value of $68 billion. (WSJ)

2. Drugmakers are fighting a ballot measure in California that would cap drug prices by preventing government programs like Medicaid from paying more for drugs than what Veterans Affairs pays. A survey found that two-thirds of potential voters support the measure. (Stat)

3. Only about 18% of seniors used the internet to obtain health information in 2014, a new study found. That compares to the roughly 60% of all adults who use the web to access health-related information. (LAT)

4. A high court judge in London ruled that the National Health Service can cover Gilead Sciences' Truvada as a preventative medication against HIV. The NHS had said funding for the treatment should be the responsibility of local health authorities. (Reuters)

5. Pfizer said revenue rose 11% in the second quarter of 2016. However, sales numbers for some of its key branded products, like its Prevnar vaccine, disappointed analysts. (Reuters)